PMID- 27062913
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20180329
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 113
IP  - Pt A
DP  - 2017 Feb
TI  - CB(1) cannabinoid receptor-mediated anandamide signalling reduces the defensive 
      behaviour evoked through GABA(A) receptor blockade in the dorsomedial division of 
      the ventromedial hypothalamus.
PG  - 156-166
LID - S0028-3908(16)30139-3 [pii]
LID - 10.1016/j.neuropharm.2016.04.003 [doi]
AB  - The effects of cannabinoids in brain areas expressing cannabinoid receptors, such 
      as hypothalamic nuclei, are not yet well known. Several studies have demonstrated 
      the role of hypothalamic nuclei in the organisation of behavioural responses 
      induced through innate fear and panic attacks. Panic-prone states are 
      experimentally induced in laboratory animals through a reduction in the GABAergic 
      activity. The aim of the present study was to examine panic-like elaborated 
      defensive behaviour evoked by GABA(A) receptor blockade with bicuculline (BIC) in 
      the dorsomedial division of the ventromedial hypothalamus (VMHdm). We also aimed 
      to characterise the involvement of endocannabinoids and the CB(1) cannabinoid 
      receptor in the modulation of elaborated defence behavioural responses organised 
      with the VMHdm. The guide-cannula was stereotaxicaly implanted in VMHdm and the 
      animals were treated with anandamide (AEA) at different doses, and the effective 
      dose was used after the pre-treatment with the CB(1) receptor antagonist AM251, 
      followed by GABA(A) receptor blockade in VMHdm. The results showed that the 
      intra-hypothalamic administration of AEA at an intermediate dose (5 pmol) 
      attenuated defence responses induced through the intra-VMHdm microinjection of 
      bicuculline (40 ng). This effect, however, was inhibited when applied central 
      microinjection of the CB(1) receptor antagonist AM251 in the VMHdm. Moreover, 
      AM251 potentiates de non-oriented escape induced by bicuculline, effect blocked 
      by pre-treatment with the TRPV(1) channel antagonist 6-I-CPS. These results 
      indicate that AEA modulates the pro-aversive effects of intra-VMHdm-bicuculline 
      treatment, recruiting CB(1) cannabinoid receptors and the TRPV1 channel is 
      involved in the AM251-related potentiation of bicuculline effects on non-oriented 
      escape behaviour.
CI  - Copyright A(c) 2016 Elsevier Ltd. All rights reserved.
FAU - Dos Anjos-Garcia, Tayllon
AU  - Dos Anjos-Garcia T
AD  - Laboratory of Neuroanatomy and Neuropsychobiology, Department of Pharmacology, 
      Ribeirao Preto Medical School of the University of Sao Paulo (USP), Av. 
      Bandeirantes 3900, Ribeirao Preto, Sao Paulo, 14049-900, Brazil.
FAU - Ullah, Farhad
AU  - Ullah F
AD  - Laboratory of Neuroanatomy and Neuropsychobiology, Department of Pharmacology, 
      Ribeirao Preto Medical School of the University of Sao Paulo (USP), Av. 
      Bandeirantes 3900, Ribeirao Preto, Sao Paulo, 14049-900, Brazil.
FAU - Falconi-Sobrinho, Luiz Luciano
AU  - Falconi-Sobrinho LL
AD  - Laboratory of Neuroanatomy and Neuropsychobiology, Department of Pharmacology, 
      Ribeirao Preto Medical School of the University of Sao Paulo (USP), Av. 
      Bandeirantes 3900, Ribeirao Preto, Sao Paulo, 14049-900, Brazil.
FAU - Coimbra, Norberto Cysne
AU  - Coimbra NC
AD  - Laboratory of Neuroanatomy and Neuropsychobiology, Department of Pharmacology, 
      Ribeirao Preto Medical School of the University of Sao Paulo (USP), Av. 
      Bandeirantes 3900, Ribeirao Preto, Sao Paulo, 14049-900, Brazil; 
      NAP-USP-Neurobiology of Emotions (NuPNE) Research Centre, FMRP-USP, Ribeirao 
      Preto, Sao Paulo, Brazil. Electronic address: nccoimbr@fmrp.usp.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160408
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Arachidonic Acids)
RN  - 0 (Endocannabinoids)
RN  - 0 (GABA-A Receptor Antagonists)
RN  - 0 (Piperidines)
RN  - 0 (Polyunsaturated Alkamides)
RN  - 0 (Pyrazoles)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 0 (Receptors, GABA-A)
RN  - 0 (TRPV Cation Channels)
RN  - 0 (Trpv1 protein, rat)
RN  - 3I4FA44MAI (AM 251)
RN  - UR5G69TJKH (anandamide)
RN  - Y37615DVKC (Bicuculline)
SB  - IM
MH  - Animals
MH  - Arachidonic Acids/administration & dosage
MH  - Bicuculline/administration & dosage
MH  - Disease Models, Animal
MH  - Endocannabinoids/administration & dosage
MH  - Escape Reaction/drug effects/*physiology
MH  - GABA-A Receptor Antagonists/administration & dosage
MH  - Male
MH  - Panic Disorder/chemically induced/physiopathology
MH  - Piperidines/administration & dosage
MH  - Polyunsaturated Alkamides/administration & dosage
MH  - Pyrazoles/administration & dosage
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Cannabinoid, CB1/agonists/antagonists & inhibitors/*physiology
MH  - Receptors, GABA-A/*physiology
MH  - TRPV Cation Channels/*physiology
MH  - Ventromedial Hypothalamic Nucleus/drug effects/*physiology
OTO - NOTNLM
OT  - CB(1) cannabinoid receptor
OT  - Defensive behaviour
OT  - Endocannabinoid neuromodulators
OT  - GABA(A) receptor
OT  - TRPV1 channel
OT  - Ventromedial hypothalamus
EDAT- 2016/11/05 06:00
MHDA- 2017/07/01 06:00
CRDT- 2016/11/05 06:00
PHST- 2015/08/12 00:00 [received]
PHST- 2016/03/22 00:00 [revised]
PHST- 2016/04/04 00:00 [accepted]
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
PHST- 2016/11/05 06:00 [entrez]
AID - S0028-3908(16)30139-3 [pii]
AID - 10.1016/j.neuropharm.2016.04.003 [doi]
PST - ppublish
SO  - Neuropharmacology. 2017 Feb;113(Pt A):156-166. doi: 
      10.1016/j.neuropharm.2016.04.003. Epub 2016 Apr 8.